Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents Article Swipe
Rebecca Evans
,
Barnaby C Reeves
,
Maureen G. Maguire
,
Daniel Martín
,
Alyson Muldrew
,
Tünde Pető
,
Chris Rogers
,
Usha Chakravarthy
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1001/jamaophthalmol.2020.3001
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1001/jamaophthalmol.2020.3001
Greater variation in retinal thickness in eyes with nAMD during treatment with anti-VEGF was associated with worse BCVA and development of fibrosis and macular atrophy in these post hoc analyses, despite protocol-directed treatment frequency. Practitioners may want to consider variation in retinal thickness when advising patients about their prognosis.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1001/jamaophthalmol.2020.3001
- https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2769560/jamaophthalmology_evans_2020_oi_200060_1601757551.32075.pdf
- OA Status
- hybrid
- Cited By
- 128
- References
- 35
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3072257851
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3072257851Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1001/jamaophthalmol.2020.3001Digital Object Identifier
- Title
-
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor AgentsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-08-20Full publication date if available
- Authors
-
Rebecca Evans, Barnaby C Reeves, Maureen G. Maguire, Daniel Martín, Alyson Muldrew, Tünde Pető, Chris Rogers, Usha ChakravarthyList of authors in order
- Landing page
-
https://doi.org/10.1001/jamaophthalmol.2020.3001Publisher landing page
- PDF URL
-
https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2769560/jamaophthalmology_evans_2020_oi_200060_1601757551.32075.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2769560/jamaophthalmology_evans_2020_oi_200060_1601757551.32075.pdfDirect OA link when available
- Concepts
-
Medicine, Macular degeneration, Ophthalmology, Choroidal neovascularization, Visual acuity, Quartile, Retinal, Ranibizumab, Randomized controlled trial, Bevacizumab, Surgery, Internal medicine, Confidence interval, ChemotherapyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
128Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 23, 2024: 28, 2023: 21, 2022: 32, 2021: 19Per-year citation counts (last 5 years)
- References (count)
-
35Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3072257851 |
|---|---|
| doi | https://doi.org/10.1001/jamaophthalmol.2020.3001 |
| ids.doi | https://doi.org/10.1001/jamaophthalmol.2020.3001 |
| ids.mag | 3072257851 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/32816002 |
| ids.openalex | https://openalex.org/W3072257851 |
| fwci | 14.90759088 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000368 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Aged |
| mesh[1].qualifier_ui | Q000008 |
| mesh[1].descriptor_ui | D020533 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | administration & dosage |
| mesh[1].descriptor_name | Angiogenesis Inhibitors |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D000068258 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Bevacizumab |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D005260 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Female |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D006801 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Humans |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D008297 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Male |
| mesh[6].qualifier_ui | Q000008 |
| mesh[6].descriptor_ui | D000069579 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | administration & dosage |
| mesh[6].descriptor_name | Ranibizumab |
| mesh[7].qualifier_ui | Q000473 |
| mesh[7].descriptor_ui | D012160 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | pathology |
| mesh[7].descriptor_name | Retina |
| mesh[8].qualifier_ui | Q000379 |
| mesh[8].descriptor_ui | D041623 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | methods |
| mesh[8].descriptor_name | Tomography, Optical Coherence |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D016896 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Treatment Outcome |
| mesh[10].qualifier_ui | Q000037 |
| mesh[10].descriptor_ui | D042461 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | antagonists & inhibitors |
| mesh[10].descriptor_name | Vascular Endothelial Growth Factor A |
| mesh[11].qualifier_ui | Q000502 |
| mesh[11].descriptor_ui | D014792 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | physiology |
| mesh[11].descriptor_name | Visual Acuity |
| mesh[12].qualifier_ui | Q000175 |
| mesh[12].descriptor_ui | D057135 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | diagnosis |
| mesh[12].descriptor_name | Wet Macular Degeneration |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D057135 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Wet Macular Degeneration |
| mesh[14].qualifier_ui | Q000503 |
| mesh[14].descriptor_ui | D057135 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | physiopathology |
| mesh[14].descriptor_name | Wet Macular Degeneration |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D000368 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Aged |
| mesh[16].qualifier_ui | Q000008 |
| mesh[16].descriptor_ui | D020533 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | administration & dosage |
| mesh[16].descriptor_name | Angiogenesis Inhibitors |
| mesh[17].qualifier_ui | Q000008 |
| mesh[17].descriptor_ui | D000068258 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | administration & dosage |
| mesh[17].descriptor_name | Bevacizumab |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D005260 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Female |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D006801 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Humans |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D008297 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Male |
| mesh[21].qualifier_ui | Q000008 |
| mesh[21].descriptor_ui | D000069579 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | administration & dosage |
| mesh[21].descriptor_name | Ranibizumab |
| mesh[22].qualifier_ui | Q000473 |
| mesh[22].descriptor_ui | D012160 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | pathology |
| mesh[22].descriptor_name | Retina |
| mesh[23].qualifier_ui | Q000379 |
| mesh[23].descriptor_ui | D041623 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | methods |
| mesh[23].descriptor_name | Tomography, Optical Coherence |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D016896 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Treatment Outcome |
| mesh[25].qualifier_ui | Q000037 |
| mesh[25].descriptor_ui | D042461 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | antagonists & inhibitors |
| mesh[25].descriptor_name | Vascular Endothelial Growth Factor A |
| mesh[26].qualifier_ui | Q000502 |
| mesh[26].descriptor_ui | D014792 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | physiology |
| mesh[26].descriptor_name | Visual Acuity |
| mesh[27].qualifier_ui | Q000175 |
| mesh[27].descriptor_ui | D057135 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | diagnosis |
| mesh[27].descriptor_name | Wet Macular Degeneration |
| mesh[28].qualifier_ui | Q000188 |
| mesh[28].descriptor_ui | D057135 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | drug therapy |
| mesh[28].descriptor_name | Wet Macular Degeneration |
| mesh[29].qualifier_ui | Q000503 |
| mesh[29].descriptor_ui | D057135 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | physiopathology |
| mesh[29].descriptor_name | Wet Macular Degeneration |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D000368 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Aged |
| mesh[31].qualifier_ui | Q000008 |
| mesh[31].descriptor_ui | D020533 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | administration & dosage |
| mesh[31].descriptor_name | Angiogenesis Inhibitors |
| mesh[32].qualifier_ui | Q000008 |
| mesh[32].descriptor_ui | D000068258 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | administration & dosage |
| mesh[32].descriptor_name | Bevacizumab |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D005260 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Female |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D006801 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Humans |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D008297 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Male |
| mesh[36].qualifier_ui | Q000008 |
| mesh[36].descriptor_ui | D000069579 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | administration & dosage |
| mesh[36].descriptor_name | Ranibizumab |
| mesh[37].qualifier_ui | Q000473 |
| mesh[37].descriptor_ui | D012160 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | pathology |
| mesh[37].descriptor_name | Retina |
| mesh[38].qualifier_ui | Q000379 |
| mesh[38].descriptor_ui | D041623 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | methods |
| mesh[38].descriptor_name | Tomography, Optical Coherence |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D016896 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Treatment Outcome |
| mesh[40].qualifier_ui | Q000037 |
| mesh[40].descriptor_ui | D042461 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | antagonists & inhibitors |
| mesh[40].descriptor_name | Vascular Endothelial Growth Factor A |
| mesh[41].qualifier_ui | Q000502 |
| mesh[41].descriptor_ui | D014792 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | physiology |
| mesh[41].descriptor_name | Visual Acuity |
| mesh[42].qualifier_ui | Q000175 |
| mesh[42].descriptor_ui | D057135 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | diagnosis |
| mesh[42].descriptor_name | Wet Macular Degeneration |
| mesh[43].qualifier_ui | Q000188 |
| mesh[43].descriptor_ui | D057135 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | drug therapy |
| mesh[43].descriptor_name | Wet Macular Degeneration |
| mesh[44].qualifier_ui | Q000503 |
| mesh[44].descriptor_ui | D057135 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | physiopathology |
| mesh[44].descriptor_name | Wet Macular Degeneration |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D000368 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Aged |
| mesh[46].qualifier_ui | Q000008 |
| mesh[46].descriptor_ui | D020533 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | administration & dosage |
| mesh[46].descriptor_name | Angiogenesis Inhibitors |
| mesh[47].qualifier_ui | Q000008 |
| mesh[47].descriptor_ui | D000068258 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | administration & dosage |
| mesh[47].descriptor_name | Bevacizumab |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D005260 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Female |
| mesh[49].qualifier_ui | |
| mesh[49].descriptor_ui | D006801 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | |
| mesh[49].descriptor_name | Humans |
| type | article |
| title | Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents |
| biblio.issue | 10 |
| biblio.volume | 138 |
| biblio.last_page | 1043 |
| biblio.first_page | 1043 |
| topics[0].id | https://openalex.org/T10170 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2731 |
| topics[0].subfield.display_name | Ophthalmology |
| topics[0].display_name | Retinal Diseases and Treatments |
| topics[1].id | https://openalex.org/T11438 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9995999932289124 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2741 |
| topics[1].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[1].display_name | Retinal Imaging and Analysis |
| topics[2].id | https://openalex.org/T12599 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9980000257492065 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2731 |
| topics[2].subfield.display_name | Ophthalmology |
| topics[2].display_name | Retinal and Optic Conditions |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9220728874206543 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2776403814 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8914201259613037 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q27429789 |
| concepts[1].display_name | Macular degeneration |
| concepts[2].id | https://openalex.org/C118487528 |
| concepts[2].level | 1 |
| concepts[2].score | 0.7297067642211914 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q161437 |
| concepts[2].display_name | Ophthalmology |
| concepts[3].id | https://openalex.org/C2781359195 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6721762418746948 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q5105209 |
| concepts[3].display_name | Choroidal neovascularization |
| concepts[4].id | https://openalex.org/C2778257484 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6703444719314575 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q555066 |
| concepts[4].display_name | Visual acuity |
| concepts[5].id | https://openalex.org/C68443243 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5671498775482178 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2786686 |
| concepts[5].display_name | Quartile |
| concepts[6].id | https://openalex.org/C2780827179 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5551987886428833 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q422001 |
| concepts[6].display_name | Retinal |
| concepts[7].id | https://openalex.org/C2781100027 |
| concepts[7].level | 4 |
| concepts[7].score | 0.489928662776947 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q414270 |
| concepts[7].display_name | Ranibizumab |
| concepts[8].id | https://openalex.org/C168563851 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4578408896923065 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[8].display_name | Randomized controlled trial |
| concepts[9].id | https://openalex.org/C2777802072 |
| concepts[9].level | 3 |
| concepts[9].score | 0.3908894658088684 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q413299 |
| concepts[9].display_name | Bevacizumab |
| concepts[10].id | https://openalex.org/C141071460 |
| concepts[10].level | 1 |
| concepts[10].score | 0.30517029762268066 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[10].display_name | Surgery |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.18824002146720886 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| concepts[12].id | https://openalex.org/C44249647 |
| concepts[12].level | 2 |
| concepts[12].score | 0.0984068512916565 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[12].display_name | Confidence interval |
| concepts[13].id | https://openalex.org/C2776694085 |
| concepts[13].level | 2 |
| concepts[13].score | 0.06531906127929688 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[13].display_name | Chemotherapy |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9220728874206543 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/macular-degeneration |
| keywords[1].score | 0.8914201259613037 |
| keywords[1].display_name | Macular degeneration |
| keywords[2].id | https://openalex.org/keywords/ophthalmology |
| keywords[2].score | 0.7297067642211914 |
| keywords[2].display_name | Ophthalmology |
| keywords[3].id | https://openalex.org/keywords/choroidal-neovascularization |
| keywords[3].score | 0.6721762418746948 |
| keywords[3].display_name | Choroidal neovascularization |
| keywords[4].id | https://openalex.org/keywords/visual-acuity |
| keywords[4].score | 0.6703444719314575 |
| keywords[4].display_name | Visual acuity |
| keywords[5].id | https://openalex.org/keywords/quartile |
| keywords[5].score | 0.5671498775482178 |
| keywords[5].display_name | Quartile |
| keywords[6].id | https://openalex.org/keywords/retinal |
| keywords[6].score | 0.5551987886428833 |
| keywords[6].display_name | Retinal |
| keywords[7].id | https://openalex.org/keywords/ranibizumab |
| keywords[7].score | 0.489928662776947 |
| keywords[7].display_name | Ranibizumab |
| keywords[8].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[8].score | 0.4578408896923065 |
| keywords[8].display_name | Randomized controlled trial |
| keywords[9].id | https://openalex.org/keywords/bevacizumab |
| keywords[9].score | 0.3908894658088684 |
| keywords[9].display_name | Bevacizumab |
| keywords[10].id | https://openalex.org/keywords/surgery |
| keywords[10].score | 0.30517029762268066 |
| keywords[10].display_name | Surgery |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.18824002146720886 |
| keywords[11].display_name | Internal medicine |
| keywords[12].id | https://openalex.org/keywords/confidence-interval |
| keywords[12].score | 0.0984068512916565 |
| keywords[12].display_name | Confidence interval |
| keywords[13].id | https://openalex.org/keywords/chemotherapy |
| keywords[13].score | 0.06531906127929688 |
| keywords[13].display_name | Chemotherapy |
| language | en |
| locations[0].id | doi:10.1001/jamaophthalmol.2020.3001 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S68724622 |
| locations[0].source.issn | 2168-6165, 2168-6173 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 2168-6165 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | JAMA Ophthalmology |
| locations[0].source.host_organization | https://openalex.org/P4310320259 |
| locations[0].source.host_organization_name | American Medical Association |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320259 |
| locations[0].source.host_organization_lineage_names | American Medical Association |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2769560/jamaophthalmology_evans_2020_oi_200060_1601757551.32075.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | JAMA Ophthalmology |
| locations[0].landing_page_url | https://doi.org/10.1001/jamaophthalmol.2020.3001 |
| locations[1].id | pmid:32816002 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | JAMA ophthalmology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/32816002 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:7441468 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | cc-by |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | JAMA Ophthalmol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7441468 |
| locations[3].id | pmh:oai:research-information.bris.ac.uk:publications/adefa907-3f6e-46c1-846a-75829e4f3b18 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306400895 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Bristol Research (University of Bristol) |
| locations[3].source.host_organization | https://openalex.org/I36234482 |
| locations[3].source.host_organization_name | University of Bristol |
| locations[3].source.host_organization_lineage | https://openalex.org/I36234482 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://hdl.handle.net/1983/adefa907-3f6e-46c1-846a-75829e4f3b18 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5054954472 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-7119-8187 |
| authorships[0].author.display_name | Rebecca Evans |
| authorships[0].countries | GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2801520950, https://openalex.org/I36234482 |
| authorships[0].affiliations[0].raw_affiliation_string | Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom |
| authorships[0].institutions[0].id | https://openalex.org/I2801520950 |
| authorships[0].institutions[0].ror | https://ror.org/039fp5n52 |
| authorships[0].institutions[0].type | nonprofit |
| authorships[0].institutions[0].lineage | https://openalex.org/I2801520950 |
| authorships[0].institutions[0].country_code | GB |
| authorships[0].institutions[0].display_name | At Bristol |
| authorships[0].institutions[1].id | https://openalex.org/I36234482 |
| authorships[0].institutions[1].ror | https://ror.org/0524sp257 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I36234482 |
| authorships[0].institutions[1].country_code | GB |
| authorships[0].institutions[1].display_name | University of Bristol |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Rebecca N. Evans |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom |
| authorships[1].author.id | https://openalex.org/A5049611346 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5101-9487 |
| authorships[1].author.display_name | Barnaby C Reeves |
| authorships[1].countries | GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2801520950, https://openalex.org/I36234482 |
| authorships[1].affiliations[0].raw_affiliation_string | Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom |
| authorships[1].institutions[0].id | https://openalex.org/I2801520950 |
| authorships[1].institutions[0].ror | https://ror.org/039fp5n52 |
| authorships[1].institutions[0].type | nonprofit |
| authorships[1].institutions[0].lineage | https://openalex.org/I2801520950 |
| authorships[1].institutions[0].country_code | GB |
| authorships[1].institutions[0].display_name | At Bristol |
| authorships[1].institutions[1].id | https://openalex.org/I36234482 |
| authorships[1].institutions[1].ror | https://ror.org/0524sp257 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I36234482 |
| authorships[1].institutions[1].country_code | GB |
| authorships[1].institutions[1].display_name | University of Bristol |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Barnaby C. Reeves |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom |
| authorships[2].author.id | https://openalex.org/A5091736159 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4249-2467 |
| authorships[2].author.display_name | Maureen G. Maguire |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I79576946 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Ophthalmology, University of Pennsylvania, Philadelphia |
| authorships[2].institutions[0].id | https://openalex.org/I79576946 |
| authorships[2].institutions[0].ror | https://ror.org/00b30xv10 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I79576946 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | University of Pennsylvania |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Maureen G. Maguire |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Ophthalmology, University of Pennsylvania, Philadelphia |
| authorships[3].author.id | https://openalex.org/A5020800294 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-4488-2538 |
| authorships[3].author.display_name | Daniel Martín |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1316902750, https://openalex.org/I4210158593 |
| authorships[3].affiliations[0].raw_affiliation_string | Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio |
| authorships[3].institutions[0].id | https://openalex.org/I1316902750 |
| authorships[3].institutions[0].ror | https://ror.org/03xjacd83 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I1316902750 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Cleveland Clinic |
| authorships[3].institutions[1].id | https://openalex.org/I4210158593 |
| authorships[3].institutions[1].ror | https://ror.org/051xfzj96 |
| authorships[3].institutions[1].type | healthcare |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210158593 |
| authorships[3].institutions[1].country_code | US |
| authorships[3].institutions[1].display_name | Cleveland Eye Clinic |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Daniel F. Martin |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio |
| authorships[4].author.id | https://openalex.org/A5111391979 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Alyson Muldrew |
| authorships[4].affiliations[0].raw_affiliation_string | Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Alyson Muldrew |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland |
| authorships[5].author.id | https://openalex.org/A5018227698 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-6265-0381 |
| authorships[5].author.display_name | Tünde Pető |
| authorships[5].affiliations[0].raw_affiliation_string | Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Tunde Peto |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland |
| authorships[6].author.id | https://openalex.org/A5007945636 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-9624-2615 |
| authorships[6].author.display_name | Chris Rogers |
| authorships[6].countries | GB |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I2801520950, https://openalex.org/I36234482 |
| authorships[6].affiliations[0].raw_affiliation_string | Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom |
| authorships[6].institutions[0].id | https://openalex.org/I2801520950 |
| authorships[6].institutions[0].ror | https://ror.org/039fp5n52 |
| authorships[6].institutions[0].type | nonprofit |
| authorships[6].institutions[0].lineage | https://openalex.org/I2801520950 |
| authorships[6].institutions[0].country_code | GB |
| authorships[6].institutions[0].display_name | At Bristol |
| authorships[6].institutions[1].id | https://openalex.org/I36234482 |
| authorships[6].institutions[1].ror | https://ror.org/0524sp257 |
| authorships[6].institutions[1].type | education |
| authorships[6].institutions[1].lineage | https://openalex.org/I36234482 |
| authorships[6].institutions[1].country_code | GB |
| authorships[6].institutions[1].display_name | University of Bristol |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Chris Rogers |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom |
| authorships[7].author.id | https://openalex.org/A5019521414 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-2606-3734 |
| authorships[7].author.display_name | Usha Chakravarthy |
| authorships[7].affiliations[0].raw_affiliation_string | Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Usha Chakravarthy |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2769560/jamaophthalmology_evans_2020_oi_200060_1601757551.32075.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10170 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2731 |
| primary_topic.subfield.display_name | Ophthalmology |
| primary_topic.display_name | Retinal Diseases and Treatments |
| related_works | https://openalex.org/W2014260690, https://openalex.org/W2079794035, https://openalex.org/W2124415048, https://openalex.org/W1663750035, https://openalex.org/W2024548441, https://openalex.org/W2062742148, https://openalex.org/W3203955741, https://openalex.org/W2029053482, https://openalex.org/W1507570872, https://openalex.org/W2343066505 |
| cited_by_count | 128 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 23 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 28 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 21 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 32 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 19 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 5 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1001/jamaophthalmol.2020.3001 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S68724622 |
| best_oa_location.source.issn | 2168-6165, 2168-6173 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 2168-6165 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | JAMA Ophthalmology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320259 |
| best_oa_location.source.host_organization_name | American Medical Association |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320259 |
| best_oa_location.source.host_organization_lineage_names | American Medical Association |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2769560/jamaophthalmology_evans_2020_oi_200060_1601757551.32075.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | JAMA Ophthalmology |
| best_oa_location.landing_page_url | https://doi.org/10.1001/jamaophthalmol.2020.3001 |
| primary_location.id | doi:10.1001/jamaophthalmol.2020.3001 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S68724622 |
| primary_location.source.issn | 2168-6165, 2168-6173 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 2168-6165 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | JAMA Ophthalmology |
| primary_location.source.host_organization | https://openalex.org/P4310320259 |
| primary_location.source.host_organization_name | American Medical Association |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320259 |
| primary_location.source.host_organization_lineage_names | American Medical Association |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2769560/jamaophthalmology_evans_2020_oi_200060_1601757551.32075.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | JAMA Ophthalmology |
| primary_location.landing_page_url | https://doi.org/10.1001/jamaophthalmol.2020.3001 |
| publication_date | 2020-08-20 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W6680603607, https://openalex.org/W2418059050, https://openalex.org/W2093646832, https://openalex.org/W2804532233, https://openalex.org/W1986457383, https://openalex.org/W2266679784, https://openalex.org/W2584295152, https://openalex.org/W1481978003, https://openalex.org/W1500728559, https://openalex.org/W2146673937, https://openalex.org/W2154073405, https://openalex.org/W1935342590, https://openalex.org/W2891521689, https://openalex.org/W2609395803, https://openalex.org/W2102946567, https://openalex.org/W2753708825, https://openalex.org/W2545082692, https://openalex.org/W2965769306, https://openalex.org/W2788454982, https://openalex.org/W2063028754, https://openalex.org/W2074575505, https://openalex.org/W2910898668, https://openalex.org/W2766256148, https://openalex.org/W2467975538, https://openalex.org/W2132899855, https://openalex.org/W2020008658, https://openalex.org/W2108445835, https://openalex.org/W2104208472, https://openalex.org/W2096097549, https://openalex.org/W2895700191, https://openalex.org/W3029640339, https://openalex.org/W2140181275, https://openalex.org/W2738996050, https://openalex.org/W2778040254, https://openalex.org/W2412348844 |
| referenced_works_count | 35 |
| abstract_inverted_index.in | 2, 5, 25, 40 |
| abstract_inverted_index.of | 20 |
| abstract_inverted_index.to | 37 |
| abstract_inverted_index.and | 18, 22 |
| abstract_inverted_index.hoc | 28 |
| abstract_inverted_index.may | 35 |
| abstract_inverted_index.was | 13 |
| abstract_inverted_index.BCVA | 17 |
| abstract_inverted_index.eyes | 6 |
| abstract_inverted_index.nAMD | 8 |
| abstract_inverted_index.post | 27 |
| abstract_inverted_index.want | 36 |
| abstract_inverted_index.when | 43 |
| abstract_inverted_index.with | 7, 11, 15 |
| abstract_inverted_index.about | 46 |
| abstract_inverted_index.their | 47 |
| abstract_inverted_index.these | 26 |
| abstract_inverted_index.worse | 16 |
| abstract_inverted_index.during | 9 |
| abstract_inverted_index.Greater | 0 |
| abstract_inverted_index.atrophy | 24 |
| abstract_inverted_index.despite | 30 |
| abstract_inverted_index.macular | 23 |
| abstract_inverted_index.retinal | 3, 41 |
| abstract_inverted_index.advising | 44 |
| abstract_inverted_index.consider | 38 |
| abstract_inverted_index.fibrosis | 21 |
| abstract_inverted_index.patients | 45 |
| abstract_inverted_index.analyses, | 29 |
| abstract_inverted_index.anti-VEGF | 12 |
| abstract_inverted_index.thickness | 4, 42 |
| abstract_inverted_index.treatment | 10, 32 |
| abstract_inverted_index.variation | 1, 39 |
| abstract_inverted_index.associated | 14 |
| abstract_inverted_index.frequency. | 33 |
| abstract_inverted_index.prognosis. | 48 |
| abstract_inverted_index.development | 19 |
| abstract_inverted_index.Practitioners | 34 |
| abstract_inverted_index.protocol-directed | 31 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5049611346 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 8 |
| corresponding_institution_ids | https://openalex.org/I2801520950, https://openalex.org/I36234482 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.99145007 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |